ORIGINAL PAPER

# AgI nanoparticles as a remarkable catalyst in the synthesis of (amidoalkyl)naphthol and oxazine derivatives: an eco-friendly approach

Javad Safaei Ghomi • Safura Zahedi • Mohammad Ali Ghasemzadeh

Received: 29 August 2013 / Accepted: 13 February 2014 / Published online: 13 March 2014 - Springer-Verlag Wien 2014

Abstract AgI nanoparticles were discovered to be an effectual heterogeneous nanocatalyst for the preparation of (amidoalkyl)naphthol and oxazine derivatives under solvent-free conditions. The advantages of the present approach are short reaction times, moderate temperature, premier yields, eco-friendly reaction conditions, simple purification and good reusability of the catalyst.

Keywords Nanoparticles · 2-Naphthol · Solvent-free conditions · Oxazine · Multicomponent reactions

## Introduction

In recent years, oxazines have been considered because of their various ranges of biological properties such as antibiotic [[1\]](#page-7-0), antitumor agent [\[2](#page-7-0)], analgesic [[3\]](#page-7-0) and anticonvulsant [\[4](#page-7-0)]. In addition, benzo-1,3-oxazines are biologically active as anti-malarial [[5\]](#page-7-0), antianginal [\[6](#page-7-0)], antihypertensive [\[7](#page-7-0)] and potent antirheumatic agents [[8\]](#page-7-0). Recently, some procedures have been reported for the preparation of naphtha-oxazine derivatives using various catalysts such as p-TSA [\[9](#page-7-0)], [bmim]Br  $[10]$  $[10]$ , TMSCl/NaI  $[11]$  $[11]$ , HClO<sub>4</sub>/SiO<sub>2</sub>  $[12]$  $[12]$ , ZnO nanoparticles [\[13](#page-7-0)], Cu nanoparticles [\[14](#page-7-0)], TMSCl [[15\]](#page-7-0), thiamine hydrochloride  $[16]$  $[16]$ ,  $I_2$   $[17]$  $[17]$  and montmorillonite  $[18]$  $[18]$ . In addition, the Vilsmeier-Haack reagent is an efficient,

J. Safaei Ghomi (&) - M. A. Ghasemzadeh Department of Chemistry, Qom Branch, Islamic Azad University, Qom, Islamic Republic of Iran e-mail: safaei@kashanu.ac.ir

S. Zahedi

Department of Organic Chemistry, Faculty of Chemistry, University of Kashan, 51167 Kashan, Islamic Republic of Iran economical and mild reagent for the synthesis of highly functionalized oxazines [[19\]](#page-7-0).

Compounds containing 1,3-amino-oxygenated functional groups have been found in various important natural products and potent drugs including a number of nucleoside antibiotics and HIV protease inhibitors, such as ritonavir and lipinavir [\[20](#page-8-0)]. As well, 1-(amidoalkyl)-2 naphthols can be converted to 1-(aminomethyl)-2-naphthols by an amide hydrolysis reaction, which displays depressor and bradycardia effects in humans [\[21](#page-8-0), [22](#page-8-0)]. Multicomponent condensation of aldehydes, 2-naphthol and acetonitrile or different amides affords 1-(amidoalkyl)- 2-naphthols in the presence of Lewis or Brønsted acids such as dodecylphosphonic acid (DPA)  $[23]$  $[23]$ , H<sub>2</sub>NSO<sub>3</sub>H [\[24](#page-8-0)], oxalic acid [\[25](#page-8-0)], Fe(HSO<sub>4</sub>)<sub>3</sub> [[26\]](#page-8-0), Sr(OTf)<sub>2</sub> [\[27](#page-8-0)], I<sub>2</sub> [\[28](#page-8-0)], K<sub>5</sub>CoW<sub>12</sub>O<sub>40</sub>.3H<sub>2</sub>O [[29\]](#page-8-0), HPMo [\[30](#page-8-0)], Yb(OTf)<sub>3</sub> in ionic liquid [[31\]](#page-8-0), Indion-130 [\[32](#page-8-0)], montmorillonite K10 [\[33](#page-8-0)], TMSCl/NaI [[34\]](#page-8-0),  $Al_2O_3$ -HClO<sub>4</sub> [[35\]](#page-8-0), InCl<sub>3</sub> [\[36](#page-8-0)], 2,4,6-trichloro-1,3,5-triazine [[37\]](#page-8-0), CuPW and CuPMo [\[38](#page-8-0)], FeCl<sub>3</sub>/SiO<sub>2</sub> [[39\]](#page-8-0), H<sub>4</sub>SiW<sub>12</sub>O<sub>40</sub> [\[40](#page-8-0)], CPTS [[41\]](#page-8-0), TrCl [\[42](#page-8-0)], boric acid [\[43](#page-8-0)] and POCl<sub>3</sub>/Na<sub>2</sub>B<sub>4</sub>O<sub>7</sub> [[44\]](#page-8-0).

According to the above-mentioned importance of oxazines and (amidoalkyl)-2-naphthols, synthesis of oxazine and (amidoalkyl)-2-naphthol derivatives based on safety procedures is of principal interest for generating these products under mild conditions endured by sensitive functional groups from both synthetic and environmental points of view.

In modern science, one of the growing and important fields is nanotechnology. Because of different physical and chemical properties of nano-sized catalysts in comparison with bulk material, they attract interest from different researcher areas. Since the particles are in small size, the surface area exposed to the reactant is maximized, thus allowing more reactions to occur at the same time; hence,

1192 J. Safaei Ghomi et al.

the process is speeded up. Among various metal nanostructures, silver nanoparticles have received significant attention owing to their unusual properties and potential applications in diverse fields [[45\]](#page-8-0). In particular, advantages of silver iodide nanoparticles are available, including mild reaction conditions to produce high yields of products in short reaction times compared to traditional catalysts, and they can also be recycled [[46\]](#page-8-0). Recently, catalysis by AgI nanoparticles (NPs) and related compounds as nanocatalysts has become a field of increasing importance.

In order to achieve more efficient synthetic processes, minimize by-products and decrease the number of separate reaction steps, we have tried to develop a clean and environment-friendly approach to the synthesis of (amidoalkyl)naphthol and oxazine derivatives with high yields using AgI NPs as catalyst. The treatment of 2-naphthol, aldehyde and urea provided the synthesis of naphtho[1,2-e][1,3]oxazinones and 2-naphthol, aldehyde and acetamide resulted in 1-(amidoalkyl)-2-naphthols.

Then, the prepared (amidoalkyl)naphthols were reacted with Vilsmeier reagent in the presence of AgI NPs to give highly substituted functionalized oxazine derivatives (Scheme 1).

#### Results and discussion

For initiating optimization of the reaction conditions, we selected model reactions. Model 1: one-pot three-component condensation of acetamide, benzaldehyde and 2-naphthol; model 2: reaction of 2-naphthol, benzaldehyde and urea; model 3: cyclization of N-[(phenyl)(2-hydroxynaphthalen-1-yl)methyl]acetamide (Scheme 2).

To test the efficiency of the catalytic activity, we choose to focus our initial studies on the above-mentioned model reactions in the presence of different nanocatalysts, such as AgBr, CuCl, NiO, bulk AgI and AgI NPs (Table [1](#page-2-0)). As indicated in Table [1](#page-2-0), AgI was selected as the interesting



<span id="page-2-0"></span>



<sup>a</sup> Yields refer to isolated products

catalyst because when it was used replacing bulk AgI, the yield of the desired product was maximized.

Characterization of the AgI NPs structure was gained by SEM, XRD and FT-IR spectra. The SEM images of AgI nanoparticles are depicted in Fig. [1](#page-3-0). These results show that spherical AgI nanoparticles were obtained from  $AgNO<sub>3</sub>$  and KI with particle size in the range of 40–50 nm under ultrasound power.

The XRD pattern of AgI nanoparticles is shown in Fig. [2](#page-3-0). All reflection peaks in Fig. [2](#page-3-0) can be readily indexed to the pure cubic phase of AgI with the F-43 m space group (JCDPS no. 78-0641). THe Debye–Scherrer equation  $(D = K\lambda/\beta\cos\theta)$  is used to calculate the crystallite size diameter (D) of the AgI nanoparticles, where  $\beta$  (FWHM, full-width at half-maximum or half-width) is in radian and  $\theta$  is the position of the maximum of diffraction peak, K is the so-called shape factor, which usually takes a value of about 0.9, and  $\lambda$  is the X-ray wavelength (1.5406 Å for Cu K $\alpha$ ). Crystallite size of AgI has been found to be 48 nm.

Figure [3](#page-3-0) shows the FT-IR spectrum of AgI nanoparticles. The broad peak at 3,436 and 1,628  $\text{cm}^{-1}$  can be attributed to the (OH) stretching and bending vibrations, respectively; these peaks indicate the presence of physisorbed water linked to nanoparticles. The peak corresponding to  $\text{CH}_2$ 

stretching vibration of SDS (sodium dodecyl sulfonate) can be seen at 2,923  $\text{cm}^{-1}$ . The appearance of this peak suggests that a trace amount of SDS has been coated on the surface of AgI nanoparticles.

In another effort, we have investigated the effect of different solvents and also solvent-free conditions for the preparation of products 4a and 6a. Afterwards, it was concluded that solvent-free conditions were the best choice for the synthesis of these organic compounds. As nanoAgI was preferred as the most suitable catalyst for these reactions under solvent-free conditions, we then tried to optimize the amount of catalyst for the model reactions. Our optimization studies disclosed that the yields increased smoothly with catalyst load up to 0.03 g and then remained unchanged to 0.05 g (Table [2\)](#page-4-0). With these results, we extended our work to various aldehydes, and all of the results are shown in Tables [3](#page-4-0) and [4.](#page-5-0)

Heterogeneous catalysts are useful because of the ability to reuse of them to reduce waste. In order to study the stability of our catalyst, the reaction was run successively with the same catalyst in the same reaction. Figure [4](#page-5-0) shows the results of this survey in the model reaction 1 in the presence of AgI NPs. After completion of the reaction, the catalyst was washed well with chloroform and methanol nanoparticles

<span id="page-3-0"></span>

Fig. 3 FT-IR spectrum of AgI nanoparticles

and dried at 70  $\degree$ C for 10 h. Then the filtered catalyst was used several times with a slightly decreased activity as shown in Fig. [4.](#page-5-0) It could thus be concluded that AgI NPs with high activity and good reusability could be a satisfying catalyst for these reactions.

### Experimental

All organic materials were purchased commercially from Sigma-Aldrich and Merck and were used without further purification. All melting points were determined in capillary tubes on a Boetius melting point microscope. FT-IR spectra were recorded with KBr pellets using a Magna-IR spectrometer 550 Nicolet. NMR spectra were recorded on a Bruker 400 MHz spectrometer with CDCl<sub>3</sub> or DMSO- $d_6$  as solvent and TMS as internal standard. CHN compositions were measured by a Carlo ERBA Model EA 1108 analyzer. Powder X-ray diffraction (XRD) was carried out on a Philips diffractometer of the X'pert Company with monochromatized Cu K $\alpha$  radiation ( $\lambda = 1.5406$  Å). Microscopic morphology of products was visualized by SEM (LEO 1455VP). The mass spectra were recorded on a Joel D-30 instrument at an ionization potential of 70 eV.

## General procedure for the preparation of silver iodide nanoparticles

A solution of 0.415 g KI (25  $\times$  10<sup>-4</sup> mol) in 25 cm<sup>3</sup> distillated water was added dropwise to a solution of 0.425 g

<span id="page-4-0"></span>Table 2 Effect of solvent, temperature and catalyst load for preparation of products 4a, 6a and 7a

Product	Catalyst/g	Solvent	$T$ /°C	Time/min	Yield <sup>a</sup> /%	
4a	0.05	<b>EtOH</b>	Reflux	150	48	
	0.05	CH <sub>3</sub> CN	Reflux	120	53	
	0.05	$CH_2Cl_2$	Reflux	100	42	
	0.05	Solvent-free	140	8	90	
	0.01	Solvent-free	r.t.	240	No reaction	
	0.02	Solvent-free	110	120	15	
	0.03	EtOH	Reflux	140	15	
	0.03	Solvent-free	110	120	23	
	0.03	Solvent-free	140	8	90	
	0.03	Solvent-free	140	15	90	
	0.03	Solvent-free	160	8	90	
6a	0.05	EtOH	Reflux	150	54	
	0.05	CH <sub>3</sub> CN	Reflux	120	66	
	0.05	CH <sub>2</sub> Cl <sub>2</sub>	Reflux	100	44	
	0.01	Solvent-free	r.t.	240	No reaction	
	0.02	Solvent-free	100	120	17	
	0.03	EtOH	Reflux	120	15	
	0.03	Solvent-free	50	120	35	
	0.03	Solvent-free	110	5	89	
	0.05	Solvent-free	110	5	89	
	0.03	Solvent-free	140	5	89	
7a	0.05	Solvent-free	r.t.	180	No reaction	
	0.05	Solvent-free	40	120	33	
	0.05	Solvent-free	50	90	55	
	0.01	Solvent-free	60	70	69	
	0.02	Solvent-free	60	65	73	
	0.03	Solvent-free	70	20	88	
	0.05	Solvent-free	$70\,$	20	88	
	0.03	Solvent-free	80	20	88	

<sup>a</sup> Isolated yields

Table 3 Preparation of naphthoxazine-3-one derivatives

Products	Ar	Time/min	Yield <sup>a</sup> /%	M.p. [References]
4a	$C_6H_5$	8	90	217-219 [14]
4b	$4-MeOC6H4$	15	82	189-190 [13]
4c	$4-MeC6H4$	12	78	$163 - 165$ [13]
4d	$4-BrC_6H_4$	6	90	217-218 [14]
4e	$4-CIC_6H_4$	6	95	$204 - 206$ [14]
4f	$3-MeC6H4$	12	79	206-208
4g	$4-iPrC_6H_4$	15	92	$171 - 173$ [11]
4 <sub>h</sub>	$4-Me_2NC_6H_4$	20	80	218-219
4i	Thiophen-2-yl	7	80	209-210 [12]

<sup>a</sup> Yields refer to the pure isolated products

AgNO<sub>3</sub> (25  $\times$  10<sup>-4</sup> mol) in 25 cm<sup>3</sup> distillated water under ultrasound power in the presence of 0.2 g sodium dodecyl sulfate (SDS) as surfactant. The yellow as-synthesized precipitate was separated by centrifugation and washed with distillated water and ethanol to remove impurities for several times and then dried.

General procedure for the preparation of naphthooxazinones 4a-4i

A mixture of  $\beta$ -naphthol (0.01 mol), aldehyde (0.01 mol), urea (0.012 mol) and 0.03 g AgI NPs was finely ground and heated with stirring at  $140\degree C$  in an oil bath. The reaction was monitored by TLC. After cooling, the reaction mixture was dissolved in ethyl acetate and the mixture stirred for 5 min. The suspended solution was filtered and the heterogeneous catalyst was recovered. The ethyl acetate was evaporated and the crude product crystallized from MeOH to afford the pure product.

### General procedure for the synthesis of (amidoalkyl)naphthols 6a-6m

A mixture of 0.14 g  $\beta$ -naphthol (1 mmol), aldehyde (1 mmol), 0.07 g acetamide (1.2 mmol) and 0.03 g AgI NPs was finely ground and heated with stirring at 110  $\degree$ C in an oil bath, and the reaction was monitored by TLC. After cooling, the reaction mixture was dissolved in hot ethanol and the mixture stirred for 5 min. The reaction mixture was filtered, and the heterogeneous catalyst was recovered. Then the crude product was crystallized from EtOH (15 %) to afford the pure product. The products were characterized by comparison of their physical data with those of known compounds unless otherwise mentioned.

### General procedure for the synthesis of 1,3-oxazines 7a-7m

To a solution of acetamidonaphthols 6 (1 mmol) in DMF (1.2 equiv) and 0.03 g AgI NPs, POCl<sub>3</sub> (0.8 eqiuv) was added dropwise (15 min) at  $0^{\circ}$ C, and the reaction mixture was allowed to reach room temperature. Then the reaction mixture was stirred at  $70^{\circ}$ C for 20 min. After completion of the reaction, it was allowed to cool to room temperature. The reaction mixture was filtered, and the heterogeneous catalyst was recovered. The filtrate was poured into crushed ice and refrigerated overnight. The solution was neutralized with sodium acetate, and the crude compound was extracted with dichloromethane  $(3 \times 10 \text{ cm}^3)$  and washed with water  $(3 \times 5 \text{ cm}^3)$ . The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified through crystallization from EtOH to afford the pure product.

<span id="page-5-0"></span>Table 4 Synthesis of (amidoalkyl)naphthols and 1,3 oxazines

Entry	Aldehyde $(R)$	6	Time/ min	Yield <sup>a</sup> /%	M.p./ <sup>o</sup> C [References]	7	Time/ min	Yield <sup>a</sup> /%	M.p./ <sup>°</sup> C
1	$C_6H_5$	6a	5	89	$245 - 246$ [35]	7a	20	88	$235 - 237$
2	$4-NO_2C_6H_4$	6b	3	95	247-249 [33]	7b	20	92	$263 - 264$
3	$2-NO_2C_6H_4$	6с	$\overline{4}$	92	$178 - 180$ [33]	7с	20	92	$255 - 257$
4	$4-CIC6H4$	6d	$\overline{4}$	90	$223 - 225$ [33]	7d	20	88	$232 - 234$
5	$2,4$ -Cl <sub>2</sub> C <sub>6</sub> H <sub>3</sub>	6е	5	89	$200 - 202$ [31]	7е	20	80	$209 - 210$
6	$4-MeC6H4$	6f	10	80	$222 - 223$ [31]	7f	20	79	219-221
7	4-MeOC <sub>6</sub> H <sub>4</sub>	6g	15	84	$183 - 185$ [31]	7g	20	79	$205 - 206$
8	$4-iPrC_6H_4$	6h	20	85	220-222	7h	20	82	228-229
9	$4-BrC_6H_4$	6j	$\overline{4}$	90	227-229 [27]	7j	20	88	$237 - 239$
10	$4-OHC6H4$	6k	15	80	226-227	7k	20	87	$241 - 243$
11	$2,4-(MeO)2C6H3$	61	17	85	$227 - 229$	71	20	85	$250 - 252$
12	1-Naphthyl	бm	15	82	210-220	7 <sub>m</sub>	20	82	245-247

<sup>a</sup> Yields refer to isolated products



Fig. 4 Recoverability of AgI nanoparticles

### 1,2-Dihydro-1-(3-methylphenyl)-3H-naphtho[1,2-e]-  $[1,3]o<sub>xazine-3-one</sub>$  (4f,  $C_{19}H_{15}NO_2$ )

IR (KBr):  $\bar{v} = 3,264, 1,746, 1,515, 815, 745 \text{ cm}^{-1};$  <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 2.21$  (s, 3H, CH<sub>3</sub>), 6.12 (s, 1H, CH), 7.04–7.12 (m, 3H, Ar–H), 7.21 (t, 1H, Ar–H), 7.35–7.48 (m, 3H, Ar–H), 7.80 (d,  $J = 7.6$  Hz, 1H, Ar–H), 7.93 (d,  $J = 7.6$  Hz, 1H, Ar–H), 7.98 (d,  $J = 7.6$  Hz, 1H, Ar–H), 8.80 (s, 1H, NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 21.5$  (CH<sub>3</sub>), 54.3 (CH), 114.5, 115.0, 116.5, 117.3, 123.5, 124.6, 125.5, 127.8, 129.1, 129.2, 129.3, 130.7, 130.9, 138.6, 143.3, 147.9, 149.8 (CO) ppm; MS (EI):  $m/z = 289$  (M<sup>+</sup>).

### 1,2-Dihydro-1-(4-dimethylaminophenyl)-3H-naphtho- [1,2-e][1,3]oxazine-3-one (4h,  $C_{20}H_{18}N_2O_2$ )

IR (KBr):  $\bar{v} = 3,224, 1,734, 1,600, 850, 730 \text{ cm}^{-1}$ ; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 2.80$  (s, 6H, CH<sub>3</sub>), 6.02  $(s, 1H, CH), 6.62$  (d,  $J = 7.8$  Hz, 2H, Ar–H), 7.08 (d,  $J = 7.8$  Hz, 2H, Ar–H), 7.35 (d,  $J = 7.6$  Hz, 2H, Ar–H), 7.45 (t,  $J = 7.6$  Hz, 2H, Ar–H), 7.78 (d,  $J = 7.6$  Hz, 1H, Ar–H), 7.95 (t,  $J = 7.6$  Hz, 1H, Ar–H), 8.68 (s, 1H, NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 31.5$  (CH<sub>3</sub>), 53.9 (CH), 112.8, 115.1, 117.3, 123.1, 125.4, 126.4, 127.7, 128.1, 129.0, 130.3, 130.8, 130.9, 147.7, 150.0, 150.4 (CO) ppm; MS (EI):  $m/z = 318$  (M<sup>+</sup>).

## N-[(2-Hydroxynaphthalen-1-yl)(4-isopropylphenyl) methyl *acetamide* (6h,  $C_{22}H_{23}NO_2$ )

IR (KBr):  $\bar{v} = 3,405, 3,168, 3,058, 1,633, 1,515, 1,438, 1,370,$ 1,330, 1,275, 1,168, 986, 816, 744 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 1.14$  (d,  $J = 7.0$  Hz, 6H), 1.95 (s, 3H), 2.81  $(m, J = 7.0$  Hz, 1H), 7.06–7.11  $(m, 5H)$ , 7.19  $(t, J = 7.2$  Hz, 1H), 7.27 (t,  $J = 7.6$  Hz, 1H), 7.36 (t,  $J = 7.6$  Hz, 1H), 7.75 (d,  $J = 7.6$  Hz, 1H), 7.80 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.8$  Hz, 1H), 8.43 (d,  $J = 8.4$  Hz, 1H), 9.96 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 23.1, 24.4, 33.4, 48.3,$ 119.0, 119.4, 122.8, 123.0, 123.6, 126.3, 126.6, 126.7, 128.0, 128.9, 129.0, 129.5, 132.8, 140.3, 146.6, 153.5, 169.5 ppm; MS (EI):  $m/z = 333$  (M<sup>+</sup>).

### N-[(2-Hydroxynaphthalen-1-yl)(4-hydroxyphenyl) methyl *acetamide* (6k,  $C_{19}H_{17}NO_3$ )

IR (KBr):  $\bar{v} = 3,406, 3,180, 3,052, 1,616, 1,514, 1,438, 1,370,$ 1,330, 1,275, 1,168, 986, 813, 738 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 1.97$  (s, 3H), 7.04–7.09 (m, 5H), 7.19 (t,  $J = 7.2$  Hz, 1H), 7.25 (t,  $J = 7.2$  Hz, 1H), 7.36 (t,  $J = 7.6$  Hz, 1H), 7.77 (d,  $J = 7.6$  Hz, 1H), 7.80 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.8$  Hz, 1H), 8.55 (d,  $J = 8.4$  Hz, 1H), 9.20 (s, 1H), 9.87 (s, 1H) ppm; <sup>13</sup>C NMR  $(100 \text{ MHz}, \text{ DMSO-}d_6): \delta = 23.4, 48.5, 119.3, 120.1, 122.8,$ 123.0, 123.6, 126.3, 126.6, 126.7, 128.0, 128.9, 129.0, 129.5, 132.8, 140.3, 146.8, 153.2, 168.9 ppm; MS (EI): m/z = 307  $(M^+).$ 

### N-[(2,4-Dimethoxyphenyl)(2-hydroxynaphthalen-1-yl) methyl Jacetamide (6l,  $C_{21}H_{21}NO_4$ )

IR (KBr):  $\bar{v} = 3,406, 3,139, 1,646, 1,521, 1,506, 1,442,$ 1,400, 1,374, 1,329, 1,264, 1,242, 1,091, 1,068, 818, 764,

659 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 1.90$  (s, 3H), 3.72 (s, 6H), 6.89–7.01 (m, 2H), 7.17 (d,  $J = 8.4$  Hz, 1H), 7.29 (t,  $J = 7.2$  Hz, 1H), 7.33–7.39 (m, 2H), 7.46 (d,  $J = 8.4$  Hz, 1H), 7.74-7.79 (m, 3H), 8.55 (d,  $J = 7.6$  Hz, 1H), 9.98 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 23.3, 48.7, 55.2, 55.9, 110.4, 118.6, 118.8, 123.2,$ 126.9, 128.5, 129.1, 129.5, 129.7, 130.5, 131.6, 132.8, 144.9, 149.3, 153.7, 153.9, 170.2 ppm; MS (EI): m/  $z = 351$  (M<sup>+</sup>).

### N-[(1-Naphthyl)(2-hydroxynaphthalen-1-yl)methyl] acetamide (6m,  $C_{23}H_{19}NO_2$ )

IR (KBr):  $\bar{v} = 3,412, 3,173, 3,060, 1,642, 1,572, 1,514,$ 1,437, 1,400, 1,374, 1,332, 1,274, 1,224, 1,172, 932, 813, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ):  $\delta = 1.90$  (s, 3H), 7.22–7.29 (m, 3H), 7.39–7.44 (m, 4H), 7.61 (d,  $J = 8.4$  Hz, 1H), 7.70–7.80 (m, 3H), 7.91–8.03 (d,  $J = 7.6$  Hz, 3H), 8.70 (d,  $J = 7.6$  Hz, 1H), 10.01 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 22.9, 47.4,$ 117.6, 118.7, 119.3, 122.8, 123.5, 123.9, 125.5, 125.7, 125.9, 126.5, 126.7, 127.9, 129.0, 129.2, 129.7, 131.5, 133.3, 134.0, 137.8, 153.8, 168.9 ppm; MS (EI):  $m/z = 341$  (M<sup>+</sup>).

## $(1, 2-Dihydro-1-phenyl-3H-naphtho[1,2-e][1,3]$ oxazine-3-ylidene)malonaldehyde (7a,  $C_{21}H_{15}NO_3$ )

IR (KBr):  $\bar{v} = 3,398, 1,629, 1,515, 1,453, 1,221,828 \text{ cm}^{-1};$ <br><sup>1</sup>H NMP (400 MHz, CDCl):  $\delta = 6.24$  (c, 1H) 7.13, 7.15 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.24$  (s, 1H), 7.13–7.15  $(d, J = 7.6 \text{ Hz}, 2\text{H}), 7.17-7.21 (d, J = 7.6 \text{ Hz}, 2\text{H}), 7.48-$ 7.49 (t,  $J = 7.6$  Hz, 3H), 7.76 (t,  $J = 7.8$  Hz, 2H), 7.90 (d,  $J = 7.8$  Hz, 1H), 7.97 (d,  $J = 7.8$  Hz, 1H), 10.04 (br s, 2H, CHO), 12.33 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.6, 101.1, 113.6, 118.3, 123.2, 124.7, 127.3, 128.8,$ 129.6, 130.4, 131.7, 132.9, 134.5, 143.6, 144.9, 148.4, 162.3, 186.9 ppm; MS (EI):  $m/z = 329$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(4-nitrophenyl)-3H-naphtho-

[1,2-e][1,3]oxazine-3-ylidene]malonaldehyde

 $(7b, C_{21}H_{14}N_2O_5)$ 

IR (KBr):  $\bar{v} = 3,408, 1,632, 1,515, 1,453, 1,221, 828 \text{ cm}^{-1};$ <br><sup>1</sup>H NMP (400 MHz, CDCl):  $\delta = 6,33$  (c, 1H) 7.10, 7.14 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.23$  (s, 1H), 7.10–7.14 (d,  $J = 7.6$  Hz, 2H),  $7.17-7.21$  (d,  $J = 7.6$  Hz, 2H), 7.46–7.49 (t,  $J = 7.6$  Hz, 3H), 7.61 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.8$  Hz, 1H), 7.96 (d,  $J = 7.7$  Hz, 1H), 10.02 (br s, 2H, CHO), 12.25 (s, 1H) ppm; 13C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.3, 101.3, 113.4, 117.9, 123.3, 125.7, 127.3,$ 128.5, 128.9, 129.6, 130.4, 131.7, 131.8, 132.9, 134.5, 143.6, 144.9, 148.4, 162.6, 187.0 ppm; MS (EI):  $m/z = 374$  (M<sup>+</sup>).

#### [1,2-Dihydro-1-(2-nitrophenyl)-3H-naphtho-

[1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7c, C_{21}H_{14}N_2O_5)$ 

IR (KBr):  $\bar{v} = 3,399, 1,630, 1,515, 1,453, 1,221, 825 \text{ cm}^{-1}$ ;<br><sup>1</sup>H NMP (400 MHz, CDCl):  $\delta = 6,33$  (c, 1H) 7.10, 7.14 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.23$  (s, 1H), 7.10–7.14 (d,  $J = 7.6$  Hz, 2H),  $7.17-7.21$  (t,  $J = 7.6$  Hz, 2H), 7.46–7.49 (t,  $J = 7.7$  Hz, 3H), 7.61 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.8$  Hz, 1H), 7.96 (d,  $J = 7.8$  Hz, 1H), 10.01 (br s, 2H, CHO), 12.26 (s, 1H) ppm; 13C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 48.9, 101.1, 113.7, 118.4, 123.3, 125.7, 127.3,$ 128.5, 128.9, 129.6, 130.4, 131.7, 131.8, 132.9, 134.5, 143.2, 144.5, 148.2, 162.3, 186.8 ppm; MS (EI):  $m/z = 374$  (M<sup>+</sup>).

## [1-(4-Chlorophenyl)-1,2-dihydro-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7d, C_{21}H_{14}CINO_3)$

IR (KBr):  $\bar{v} = 3,406, 1,627, 1,515, 1,453, 1,221,$ 831 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.21$  (s, 1H),  $7.12-7.14$  (d,  $J = 7.6$  Hz, 2H),  $7.19-7.25$  (d,  $J = 7.6$  Hz, 2H), 7.46–7.49 (t,  $J = 7.7$  Hz, 3H), 7.61 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.7$  Hz, 1H), 7.96 (d,  $J = 7.7$  Hz, 1H), 10.01 (br s, 2H, CHO), 12.28 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.4$ , 101.1, 113.4, 117.9, 123.3, 125.7, 127.3, 128.5, 128.9, 129.6, 130.4, 131.7, 131.8, 132.9, 134.5, 143.6, 144.9, 148.4, 163.1, 186.7 ppm; MS (EI):  $m/z = 363$  (M<sup>+</sup>).

## [1-(2,4-Dichlorophenyl)-1,2-dihydro-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7e, C_{21}H_{13}Cl_2NO_3)$

IR (KBr):  $\bar{v} = 3,409, 1,620, 1,510, 1,449, 1,220,$ 826 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.22$  (s, 1H),  $7.19-7.25$  (d,  $J = 7.6$  Hz, 2H),  $7.49-7.62$  (d,  $J = 7.7$  Hz, 2H),  $7.65 - 7.70$  (d,  $J = 7.7$  Hz, 2H), 7.89–7.93 (d,  $J = 7.8$  Hz, 2H), 8.11 (s, 1H), 10.03 (br s, 2H, CHO), 12.28 (s, 1H) ppm; 13C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.3, 101.3, 113.4, 117.2, 123.1, 124.3,$ 126.8, 128.8, 128.9, 129.6, 130.1, 131.7, 131.8, 131.9, 134.5, 143.0, 144.8, 148.6, 162.1, 186.7 ppm; MS (EI): m/  $z = 397$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(4-methylphenyl)-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7f, C_{22}H_{17}NO_3)$

IR (KBr):  $\bar{v} = 3,408, 1,628, 1,515, 1,453, 1,219,$ 821 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 2.30$  (s, 3H), 6.20 (s, 1H), 7.10–7.13 (d,  $J = 7.6$  Hz, 2H), 7.15–7.20 (d,  $J = 7.6$  Hz, 2H), 7.42–7.48 (t,  $J = 7.7$  Hz, 3H), 7.58 (d,  $J = 7.8$  Hz, 1H), 7.84 (d,  $J = 7.7$  Hz, 1H), 7.97 (d,  $J = 7.7$  Hz, 1H), 10.03 (br s, 2H, CHO), 12.26 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 23.3, 50.2,$ 101.1, 113.4, 117.9, 123.3, 125.7, 127.3, 128.5, 128.9, 129.6, 130.4, 131.7, 131.8, 132.9, 134.5, 142.9, 144.4, 147.8, 162.2, 186.8 ppm; MS (EI):  $m/z = 343$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(4-methoxyphenyl)-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde

 $(7g, C_{22}H_{17}NO_4)$ 

IR (KBr):  $\bar{v} = 3,403, 1,624, 1,513, 1,449, 1,220,819 \text{ cm}^{-1}$ ;<br><sup>1</sup>H NMP (400 MHz CDCl):  $\delta = 3.48$  (s, 3H) 6.21 (s, 1H) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 3.48$  (s, 3H), 6.21 (s, 1H), 7.18–7.26 (d,  $J = 7.6$  Hz, 2H), 7.45–7.60 (d,  $J = 7.7$  Hz, 2H),  $7.63-7.72$  (d,  $J = 7.8$  Hz, 2H),  $7.87-7.91$  (d, <span id="page-7-0"></span> $J = 7.8$  Hz, 2H), 8.08 (s, 1H), 10.02 (br s, 2H, CHO), 12.24 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 33.5, 50.1$ , 101.1, 113.4, 117.2, 123.1, 124.3, 126.8, 128.8, 128.9, 129.6, 130.4, 131.7, 131.8, 131.9, 134.2, 143.5, 145.4, 148.4, 162.2, 187.2 ppm; MS (EI):  $m/z = 359$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(4-isopropylphenyl)-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7h, C_{24}H_{21}NO_3)$

IR (KBr):  $\bar{v} = 3,407, 1,619, 1,513, 1,454, 1,220,834 \text{ cm}^{-1}$ ;<br><sup>1</sup>H NMP (400 MHz CDCL):  $\delta = 1.19$  (d,  $I = 7.0$  Hz 6H) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 1.19$  (d,  $J = 7.0$  Hz, 6H), 2.84 (m,  $J = 7.0$  Hz, 1H), 6.20 (s, 1H), 7.19–7.25 (d,  $J = 7.6$  Hz, 3H), 7.49–7.62 (t,  $J = 7.7$  Hz, 3H), 7.89–7.93  $(t, J = 7.6$  Hz, 2H), 8.12 (m, 2H), 10.02 (br s, 2H, CHO), 12.26 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 23.2$ , 33.5, 50.3, 101.3, 113.4, 117.2, 123.1, 124.3, 126.8, 128.8, 128.9, 129.6, 130.1, 131.7, 131.8, 131.9, 134.5, 143.0, 144.8, 148.6, 162.1, 186.7 ppm; MS (EI):  $m/z = 371$  (M<sup>+</sup>).

## [1-(4-Bromophenyl)-1,2-dihydro-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7j, C_{21}H_{14}BrNO_3)$

IR (KBr):  $\bar{v} = 3,410, 1,620, 1,513, 1,446, 1,220,$ 815 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.20$  (s, 1H),  $7.13-7.15$  (d,  $J = 7.6$  Hz, 2H),  $7.18-7.20$  (d,  $J = 7.6$  Hz, 2H), 7.46–7.49 (t,  $J = 7.7$  Hz, 3H), 7.61 (d,  $J = 7.8$  Hz, 1H), 7.88 (d,  $J = 7.8$  Hz, 1H), 7.96 (d,  $J = 7.7$  Hz, 1H), 10.01 (br s, 2H, CHO), 12.27 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.5$ , 101.1, 113.3, 118.2, 123.5, 124.4, 127.3, 128.8, 128.9, 129.6, 130.2, 131.7, 131.8, 131.9, 134.5, 143.6, 145.4, 148.6, 162.4, 186.8 ppm; MS (EI):  $m/z = 406$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(4-hydroxyphenyl)-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7k, C_{21}H_{15}NO_4)$

IR (KBr):  $\bar{v} = 3,405, 1,626, 1,514, 1,449, 1,220,$ 822 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.23$  (s, 1H),  $7.18-7.24$  (d,  $J = 7.6$  Hz, 2H),  $7.47-7.63$  (d,  $J = 7.6$  Hz, 2H), 7.63–7.71 (d,  $J = 7.7$  Hz, 2H), 7.89–7.93 (d,  $J = 7.8$  Hz, 2H), 8.11 (s, 1H), 9.45 (s, 1H), 10.01 (br s, 2H, CHO), 12.29 (s, 1H) ppm; <sup>13</sup>C NMR  $(100 \text{ MHz}, \text{CDCl}_3): \delta = 50.3, 101.3, 113.4, 117.2, 123.1,$ 124.3, 126.8, 128.8, 128.9, 129.6, 130.1, 131.7, 131.8, 131.9, 134.5, 143.0, 144.8, 148.6, 162.1, 186.7 ppm; MS (EI):  $m/z = 345$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(2,4-dimethoxyphenyl)-3H-naphtho- [1,2-e]-[1,3]oxazine-3-ylidene]malonaldehyde

 $(7l, C_{23}H_{19}NO_5)$ 

IR (KBr):  $\bar{v} = 3,397, 1,628, 1,515, 1,449, 1,220,$ 821 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 3.72$  (s, 6H), 6.22 (s, 1H), 7.19–7.25 (d,  $J = 7.6$  Hz, 2H), 7.49–7.62 (d,  $J = 7.7$  Hz, 2H), 7.65–7.70 (d,  $J = 7.7$  Hz, 2H), 7.89–7.93 (d,  $J = 7.8$  Hz, 2H), 8.11 (s, 1H), 10.03 (br s, 2H, CHO), 12.28 (s, 1H) ppm;  $^{13}$ C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 50.1, 53.5, 53.6, 101.2, 113.4, 117.2, 123.1,$ 124.3, 126.8, 128.8, 128.9, 129.6, 130.2, 131.7, 131.8, 131.9, 134.5, 143.0, 144.8, 148.4, 163.6, 186.9 ppm; MS (EI):  $m/z = 389$  (M<sup>+</sup>).

## [1,2-Dihydro-1-(naphthalen-1-yl)-3H-naphtho- [1,2-e][1,3]oxazine-3-ylidene]malonaldehyde  $(7m, C_{25}H_{17}NO_3)$

IR (KBr):  $\bar{v} = 3,404, 1,623, 1,510, 1,449, 1,220,$ 826 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 7.20$ -7.27  $(m, 3H), 7.36-7.42$   $(m, 4H), 7.61$   $(d, J = 8.4 \text{ Hz}, 1H),$ 7.70–7.82 (m, 3H), 7.89–8.01 (d,  $J = 7.6$  Hz, 3H), 8.77 (d,  $J = 7.6$  Hz, 1H), 10.01 (br s, 2H, CHO), 12.27 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ):  $\delta = 53.4$ , 101.1, 118.7, 119.3, 122.8, 123.5, 123.9, 125.5, 125.7, 125.9, 126.5, 126.7, 127.9, 129.0, 129.2, 129.7, 131.5, 133.3, 134.0, 137.8, 144.8, 148.4, 163.6, 186.9 ppm; MS (EI): m/  $z = 379$  (M<sup>+</sup>).

Acknowledgments The authors are grateful to University of Kashan for supporting this work by Grant No: 159196/XX.

#### References

- 1. Sasaki K, Kusakabe Y, Esumi S (1972) J Antibiot 25:151
- 2. Johnson PY, Silver RB (1973) J Heterocycl Chem 10:1029
- 3. Lesher GY, Surrey AR (1955) J Am Chem Soc 77:636
- 4. Mosher HS, Frankel MB, Gregory M (1953) J Am Chem Soc 75:5326
- 5. Ren H, Grady S, Gamenara D, Heinzen H, Moyna P, Croft S, Kendrick H, Yardley V, Moyna G (2001) Bioorg Med Chem Lett 11:1851
- 6. Benedini F, Bertolini G, Cereda R, Dona´ G, Gromo G, Levi S, Mizrahi J, Sala A (1995) J Med Chem 38:130
- 7. Clark RD, Caroon JM, Kluge AF, Repke DB, Roszkowski AP, Strosberg AM, Baker S, Bitter SM, Okada MD (1983) J Med Chem 26:657
- 8. Matsuoka H, Ohi N, Mihara M, Suzuki H, Miyamoto K, Maruyama N, Tsuji K, Kato N, Akimoto T, Takeda Y, Yano K, Kuroki T (1997) J Med Chem 40:105
- 9. Dabiri M, Delbari A, Bazgir A (2007) Synlett 5:821
- 10. Dabiri M, Delbari A, Bazgir A (2007) Heterocycles 71:543
- 11. Sabitha G, Arundhathi K, Sudhakar K, Sastry BS, Yadav JS (2010) J Heterocycl Chem 47:272
- 12. Abbastabar Ahangar H, Mahdavinia GH, Marjani K, Hafezian A (2010) J Iran Chem Soc 7:770
- 13. Dharma Rao GB, Kaushik MP, Halve AK (2012) Tetrahedron Lett 53:2741
- 14. Kumar A, Saxena A, Dewan M, De A, Mozumdar S (2011) Tetrahedron Lett 52:4835
- 15. Lei M, Ma L, Hu L (2011) Synth Commun 41:3424
- 16. Chenggang J, Xin G, Zonglei Zh, Hangxian X, Cunde W (2010) J Chem Res 34:19
- 17. Aatika N, Päsha MA (2010) Synth Commun 40:2864
- 18. Srinivas K, Srinivasu VNV, Rajashaker B, Lingaiah N (2010) J Heterocycl Chem 47:313
- 19. Damodiran M, Panneer Selvam N, Perumal PT (2009) Tetrahedron Lett 50:5474
- <span id="page-8-0"></span>Soc 104:6465 21. Szatmari I, Fulop F (2004) Curr Org Synth 1:155
- 22. Shen AY, Tsai CT (1999) Eur J Med Chem 34:877
- 23. Zandi M, Sardarian AR (2012) CR Chimie 15:365
- 24. Patil SB, Singh PR, Surpur MP, Samant SD (2007) Ultrason Sonochem 14:515
- 25. Ansari S, Sangshetti JN, Kokare ND, Wakte PS, Shinde DB (2010) Indian J Chem Technol 17:71
- 26. Shaterian HR, Yarahmadi H, Ghashang M (2008) Bioorg Med Chem Lett 18:788
- 27. Su WK, Tang WY, Li JJ (2008) J Chem Res 6:123
- 28. Das B, Laxminarayana K, Ravikanth B, Rao BR (2007) J Mol Catal A Chem 261:180
- 29. Nagarapu L, Baseeruddin M, Apuri S, Kantevari S (2007) Catal Commun 8:1729
- 30. Jiang WQ, An LT, Zou JP (2008) Chin J Chem 26:1697
- 31. Kumar A, Rao MS, Ahmad I, Khungar B (2009) Can J Chem 87:714
- 32. Patil SB, Singh PR, Surpur MP, Samant SD (2007) Synth Commun 37:1659
- 33. Kantevari S, Vuppalapati SVN, Nagarapu L (2007) Catal Commun 8:1857
- 34. Shaterian HR, Khorami F, Amirzadeh A, Ghashang M (2009) Chin J Chem 27:815
- 35. Chavan NL, Naik PN, Nayak SK, Kusurkar RS (2010) Synth Commun 40:2941
- 36. Zhang P, Zhang ZH (2009) Monatsh Chem 140:199
- 37. Khabazzadeh H, Saidi K, Seyedi N (2009) J Chem Sci 121:429
- 38. Shaterian HR, Yarahmadi H (2008) Tetrahedron Lett 49:1297
- 39. Supale AR, Gokavi GS (2010) J Chem Sci 122:189
- 40. Wang M, Liang Y (2011) Monatsh Chem 142:153
- 41. McFarland AD, Van Duyne RP (2003) Nano Lett 3:1057
- 42. Khazaei A, Zolfigol M, Moosavi-Zare A, Abi F, Zare A, Kaveh H, Khakyzadeh V, Kazem-Rostami M, Parhami A, Torabi-Monfared H (2013) Tetrahedron 69:212
- 43. Shahrisa A, Esmati S, Gholam Hosseininazari M (2012) J Chem Sci 124:927
- 44. Jafari H, Moghanian H (2012) Lett Org Chem 9:273
- 45. Astruc D (2008) Nanoparticles and Catalysis. Wiley-VCH Verlag GmbH, Weinheim
- 46. Kushal D, Krishna M, Yogesh P, Dinesh N, Bhalchandra M (2012) Particuology 10:140